Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -10.81
- Piotroski Score 4.00
- Grade Buy
- Symbol (CUE)
- Company Cue Biopharma, Inc.
- Price $1.07
- Changes Percentage (3.88%)
- Change $0.04
- Day Low $1.01
- Day High $1.08
- Year High $3.25
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $7.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.07
- Trailing P/E Ratio -1.38
- Forward P/E Ratio -1.38
- P/E Growth -1.38
- Net Income $-50,733,000
Income Statement
Quarterly
Annual
Latest News of CUE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Jeremy Roach rescues No. 13 Baylor with buzzer-beater in 5th game after standout 4 years at Duke
Jeremy Roach made a thrilling debut with Baylor, hitting a buzzer-beating 3-pointer to secure a 99-98 victory over St. John's at the Baha Mar Championship. Roach's clutch shot came after a missed free...
By AP NEWS | 11 hours ago -
Woman rescued after getting stuck in manhole at former site of Carousel Mall in San Bernardino
Firefighters in San Bernardino rescued a woman who fell into a manhole at the Carousel Mall site. The incident occurred on Wednesday, with crews using an aerial ladder to lower a rescuer down and lift...
By CBS News | 1 day ago -
Hiker Whose Heart Stopped for 45 Minutes After Mt. Rainier Rescue Is Now Accused of Murder: Court Docs
Award-winning journalist K.C. Baker from PEOPLE reports that Michael Knapinski, who miraculously survived after his heart stopped for 45 minutes in 2020, is now charged with second-degree murder for a...
By PEOPLE.com | 1 day ago
